prednisone has been researched along with Weight Gain in 41 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To clarify whether increase of body weight in patients with early rheumatoid arthritis (RA) upon administration of prednisone is a side effect of prednisone or a result of better control of disease activity, we examined the association of prednisone and disease activity with a subsequent change in body mass index (BMI)." | 9.17 | Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? ( Bakker, MF; Bijlsma, JW; Bossema, ER; Ehrlich, JC; Geenen, R; Jacobs, JW; Jurgens, MS; Lafeber, FP; van Albada-Kuipers, IA; Welsing, PM, 2013) |
| "These results suggest that prednisone therapy aimed at improving or preserving FVC in newly- treated pulmonary sarcoidosis can often be reduced in dose, using a treatment regimen that is characterized by early dose tapering." | 7.88 | No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. ( Broos, CE; Grootenboers, MJJH; Heller, R; Hoogsteden, HC; In 't Veen, JCCM; Kool, M; Looman, CWN; Poell, LHC; van den Blink, B; van den Toorn, LM; Wapenaar, M; Wijsenbeek, MS, 2018) |
| "To report the effects of twice-daily difluprednate in a child with pars planitis (PP)." | 7.77 | Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. ( Chheda, LV; Kurz, DE; Kurz, PA, 2011) |
| "To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 7.73 | Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. ( Lu, Y; Yao, HW; Zhao, MH; Zhu, JP, 2006) |
| "To clarify whether increase of body weight in patients with early rheumatoid arthritis (RA) upon administration of prednisone is a side effect of prednisone or a result of better control of disease activity, we examined the association of prednisone and disease activity with a subsequent change in body mass index (BMI)." | 5.17 | Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? ( Bakker, MF; Bijlsma, JW; Bossema, ER; Ehrlich, JC; Geenen, R; Jacobs, JW; Jurgens, MS; Lafeber, FP; van Albada-Kuipers, IA; Welsing, PM, 2013) |
| " The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs)." | 3.96 | Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis. ( Bast, A; de Jong, SMG; Drent, M; Ebner, NM; Elfferich, MDP; Jessurun, NT; Lewis, EDO; Proesmans, VLJ, 2020) |
| "These results suggest that prednisone therapy aimed at improving or preserving FVC in newly- treated pulmonary sarcoidosis can often be reduced in dose, using a treatment regimen that is characterized by early dose tapering." | 3.88 | No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. ( Broos, CE; Grootenboers, MJJH; Heller, R; Hoogsteden, HC; In 't Veen, JCCM; Kool, M; Looman, CWN; Poell, LHC; van den Blink, B; van den Toorn, LM; Wapenaar, M; Wijsenbeek, MS, 2018) |
| "To report the effects of twice-daily difluprednate in a child with pars planitis (PP)." | 3.77 | Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. ( Chheda, LV; Kurz, DE; Kurz, PA, 2011) |
| "To study the effect of losartan, an angiotensin II antagonist, on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism." | 3.73 | Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. ( Lu, Y; Yao, HW; Zhao, MH; Zhu, JP, 2006) |
| "To report the adverse effects associated with prolonged high-dose prednisone for the treatment of autoimmune inner ear disease (AIED)." | 2.74 | Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. ( Alexander, TH; Brookhouser, PE; Derebery, JM; Espeland, MA; Gantz, BJ; Gulya, AJ; Hammerschlag, PE; Hannley, M; Harris, JP; Hughes, GB; Moscicki, R; Nelson, RA; Niparko, JK; Rauch, SD; Telian, SA; Weisman, MH, 2009) |
| "Glucocorticoid treatment in childhood acute lymphoblastic leukemia increases energy intake markedly, and this effect contributes to the excess weight gain and obesity characteristic of patients being treated for acute lymphoblastic leukemia." | 2.70 | Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. ( Brougham, M; Gibson, BE; Kelly, A; Montgomery, C; Reilly, JJ; Richardson, F, 2001) |
| "Prednisone has been shown to improve strength in Duchenne dystrophy." | 2.67 | Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) ( Brooke, MH; Cwik, VA; Fenichel, GM; Griggs, RC; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Pestronk, A; Robison, J, 1993) |
| "Boys treated with prednisone had stronger average muscle strength scores, than did boys treated with placebo as early as 10 days after starting therapy." | 2.67 | Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. ( Brooke, MH; Fenichel, GM; Griggs, RC; Mendell, JR; Miller, JP; Moxley, RT; Pestronk, A, 1991) |
| "Drug-induced weight gain is a profound side effect of numerous commonly used medications." | 1.72 | Drug-induced weight gain in the last 10 years: a descriptive study. ( Ahmed, NJ; Alahmari, A; Almalki, ZS; Alshehri, AM, 2022) |
| " We evaluated adverse side effects (ASEs) of corticosteroid treatment in patients with gMG." | 1.62 | Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis. ( Govindarajan, R; Johnson, S; Katyal, N; Narula, N, 2021) |
| " Although daily glucocorticoid therapy has been shown to extend ambulatory function in DMD, less frequent dosing is often used because of side effect concerns." | 1.46 | Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. ( Jefferies, JL; McMahon, MA; Rutter, MM; Rybalsky, I; Sawnani, H; Shellenbarger, KC; Tian, C; Wong, BL, 2017) |
| "To investigate whether long-term use of low-dose P with or without AA leads to corticosteroid-associated adverse events (CA-AEs) in mCRPC patients." | 1.43 | Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. ( Charnas, R; Chi, KN; de Bono, JS; De Porre, P; Fizazi, K; Gomella, LG; Londhe, A; McGowan, T; Miller, K; Montgomery, B; Pelhivanov, N; Rathkopf, DE; Ryan, CJ; Scher, HI; Shore, ND; Todd, MB, 2016) |
| "Prednisone was started 1 d after RAI and withdrawn after 6 wk." | 1.36 | Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. ( Bartalena, L; Compri, E; Lai, A; Marino, F; Piantanida, E; Sassi, L; Sivelli, P; Tanda, ML, 2010) |
| "Ketoconazole (KT) is a broad-spectrum antifungal agent whose pharmacological activity is based on the capability to interfere with steroid biosynthesis through an interaction with fungal cytochrome P-450 enzymes and thereby avoiding the formation of fungal walls." | 1.35 | Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses. ( Amaral, VC; Nunes, GP, 2009) |
| "Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation." | 1.35 | Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. ( Hawks, RG; Meza, JL; Post-White, JE; Sacks, N; Seibel, NL; Smith, LM; Withycombe, JS, 2009) |
| "We evaluated data from the Wegener's Granulomatosis Etanercept Trial." | 1.35 | Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. ( Anderson, T; Davis, JC; Fontaine, KR; Hoffman, GS; McCune, WJ; Merkel, PA; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Wung, PK, 2008) |
| "Prednisone has been demonstrated to have a beneficial effect on muscle strength and function in boys with Duchenne dystrophy and should be offered (at a dose of 0." | 1.33 | Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. ( Ashwal, S; Baumbach, L; Connolly, A; Florence, J; Mathews, K; McDonald, C; Moxley, RT; Pandya, S; Sussman, M; Wade, C, 2005) |
| " The recommended dosage is 0." | 1.33 | [Guideline on the use of corticosteroids in Duchenne muscular dystrophy from paediatric neurologists, neurologists and rehabilitation physicians]. ( de Groot, IJ, 2006) |
| "Obesity was defined as a body mass index (BMI) of at least 30 kg/m2." | 1.30 | Weight change and obesity after liver transplantation: incidence and risk factors. ( Everhart, JE; Hoofnagle, JH; Lake, JR; Lombardero, M; Wiesner, RH; Zetterman, RK, 1998) |
| "Although hypercholesterolemia is a frequent complication in cardiac transplant recipients, the exact mechanisms contributing to its development are not known." | 1.28 | Factors influencing the development of hypercholesterolemia after cardiac transplantation. ( Bolman, RM; Hertz, MI; Hunninghake, DB; Knutson, KR; Kubo, SH; Olivari, MT; Peters, JR, 1992) |
| "Weight gain was correlated positively with several psychologic measures but not with assessed biologic measures." | 1.28 | Weight gain with breast cancer adjuvant treatment. ( Carpenter, JT; Levine, EG; Raczynski, JM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (31.71) | 18.2507 |
| 2000's | 13 (31.71) | 29.6817 |
| 2010's | 10 (24.39) | 24.3611 |
| 2020's | 5 (12.20) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, S | 1 |
| Katyal, N | 1 |
| Narula, N | 1 |
| Govindarajan, R | 1 |
| Ahmed, NJ | 1 |
| Alshehri, AM | 1 |
| Almalki, ZS | 1 |
| Alahmari, A | 1 |
| Drent, M | 1 |
| Proesmans, VLJ | 1 |
| Elfferich, MDP | 1 |
| Jessurun, NT | 1 |
| de Jong, SMG | 1 |
| Ebner, NM | 1 |
| Lewis, EDO | 1 |
| Bast, A | 1 |
| Lee, WS | 1 |
| Lee, JJ | 1 |
| Liao, AT | 1 |
| Kao, CL | 1 |
| Wang, SL | 1 |
| Rogers, AB | 1 |
| Zaidman, CM | 1 |
| Connolly, AM | 1 |
| Broos, CE | 1 |
| Poell, LHC | 1 |
| Looman, CWN | 1 |
| In 't Veen, JCCM | 1 |
| Grootenboers, MJJH | 1 |
| Heller, R | 1 |
| van den Toorn, LM | 1 |
| Wapenaar, M | 1 |
| Hoogsteden, HC | 1 |
| Kool, M | 1 |
| Wijsenbeek, MS | 1 |
| van den Blink, B | 1 |
| Morgenstern, M | 1 |
| Singas, E | 1 |
| Zleik, B | 1 |
| Greenberg, H | 1 |
| Santosa, A | 1 |
| Ng, PS | 1 |
| Teng, GG | 1 |
| Gram-Kampmann, EM | 1 |
| Lillevang, ST | 1 |
| Detlefsen, S | 1 |
| Laursen, SB | 1 |
| Fizazi, K | 1 |
| Chi, KN | 1 |
| de Bono, JS | 1 |
| Gomella, LG | 1 |
| Miller, K | 1 |
| Rathkopf, DE | 1 |
| Ryan, CJ | 1 |
| Scher, HI | 1 |
| Shore, ND | 1 |
| De Porre, P | 1 |
| Londhe, A | 1 |
| McGowan, T | 1 |
| Pelhivanov, N | 1 |
| Charnas, R | 1 |
| Todd, MB | 1 |
| Montgomery, B | 1 |
| Wong, BL | 1 |
| Rybalsky, I | 1 |
| Shellenbarger, KC | 1 |
| Tian, C | 1 |
| McMahon, MA | 1 |
| Rutter, MM | 1 |
| Sawnani, H | 1 |
| Jefferies, JL | 1 |
| Alexander, TH | 1 |
| Weisman, MH | 1 |
| Derebery, JM | 1 |
| Espeland, MA | 1 |
| Gantz, BJ | 1 |
| Gulya, AJ | 1 |
| Hammerschlag, PE | 1 |
| Hannley, M | 1 |
| Hughes, GB | 1 |
| Moscicki, R | 1 |
| Nelson, RA | 1 |
| Niparko, JK | 1 |
| Rauch, SD | 1 |
| Telian, SA | 1 |
| Brookhouser, PE | 1 |
| Harris, JP | 1 |
| Amaral, VC | 1 |
| Nunes, GP | 1 |
| Withycombe, JS | 1 |
| Post-White, JE | 1 |
| Meza, JL | 1 |
| Hawks, RG | 1 |
| Smith, LM | 1 |
| Sacks, N | 1 |
| Seibel, NL | 1 |
| Lai, A | 1 |
| Sassi, L | 1 |
| Compri, E | 1 |
| Marino, F | 1 |
| Sivelli, P | 1 |
| Piantanida, E | 1 |
| Tanda, ML | 1 |
| Bartalena, L | 1 |
| Kurz, PA | 1 |
| Chheda, LV | 1 |
| Kurz, DE | 1 |
| Jurgens, MS | 1 |
| Jacobs, JW | 1 |
| Geenen, R | 1 |
| Bossema, ER | 1 |
| Bakker, MF | 1 |
| Bijlsma, JW | 1 |
| van Albada-Kuipers, IA | 1 |
| Ehrlich, JC | 1 |
| Lafeber, FP | 1 |
| Welsing, PM | 1 |
| Younis, S | 1 |
| Rosner, I | 1 |
| Rimar, D | 1 |
| Boulman, N | 1 |
| Rozenbaum, M | 1 |
| Odeh, M | 1 |
| Slobodin, G | 1 |
| Thiesen, AL | 1 |
| Tappenden, KA | 1 |
| McBurney, MI | 1 |
| Clandinin, MT | 1 |
| Keelan, M | 1 |
| Thomson, BK | 1 |
| Wild, GE | 1 |
| Thomson, AB | 1 |
| Campbell, C | 1 |
| Jacob, P | 1 |
| Moxley, RT | 3 |
| Ashwal, S | 1 |
| Pandya, S | 2 |
| Connolly, A | 1 |
| Florence, J | 1 |
| Mathews, K | 1 |
| Baumbach, L | 1 |
| McDonald, C | 1 |
| Sussman, M | 1 |
| Wade, C | 1 |
| Vester, U | 1 |
| Schaefer, A | 1 |
| Kranz, B | 1 |
| Wingen, AM | 1 |
| Nadalin, S | 1 |
| Paul, A | 1 |
| Malagò, M | 1 |
| Broelsch, CE | 1 |
| Hoyer, PF | 1 |
| Yao, HW | 1 |
| Zhu, JP | 1 |
| Zhao, MH | 1 |
| Lu, Y | 1 |
| Williams, JJ | 1 |
| Lund, LH | 1 |
| LaManca, J | 1 |
| Kunavarapu, C | 1 |
| Cohen, DJ | 1 |
| Heshka, S | 1 |
| Heymsfield, SB | 1 |
| Mancini, DM | 1 |
| de Groot, IJ | 1 |
| Wung, PK | 1 |
| Anderson, T | 1 |
| Fontaine, KR | 1 |
| Hoffman, GS | 1 |
| Specks, U | 1 |
| Merkel, PA | 1 |
| Spiera, R | 1 |
| Davis, JC | 1 |
| St Clair, EW | 1 |
| McCune, WJ | 1 |
| Stone, JH | 1 |
| Muthuswamy, P | 1 |
| Hu, TC | 1 |
| Carasso, B | 1 |
| Antonio, M | 1 |
| Dandamudi, N | 1 |
| Blanchette, V | 1 |
| Imbach, P | 1 |
| Andrew, M | 1 |
| Adams, M | 1 |
| McMillan, J | 1 |
| Wang, E | 1 |
| Milner, R | 1 |
| Ali, K | 1 |
| Barnard, D | 1 |
| Bernstein, M | 1 |
| Griggs, RC | 2 |
| Mendell, JR | 2 |
| Fenichel, GM | 2 |
| Brooke, MH | 2 |
| Pestronk, A | 2 |
| Miller, JP | 2 |
| Cwik, VA | 1 |
| Robison, J | 1 |
| Loftus, JK | 1 |
| Reeve, J | 1 |
| Hesp, R | 1 |
| David, J | 1 |
| Ansell, BM | 1 |
| Woo, PM | 1 |
| Groot-Loonen, JJ | 1 |
| Otten, BJ | 1 |
| van't Hof, MA | 1 |
| Lippens, RJ | 1 |
| Stoelinga, GB | 1 |
| Jacobs, SC | 1 |
| Bootsma, AL | 1 |
| Willems, PW | 1 |
| Bär, PR | 1 |
| Wokke, JH | 1 |
| Drafts, HH | 1 |
| Anjum, MR | 1 |
| Wynn, JJ | 1 |
| Mulloy, LL | 1 |
| Bowley, JN | 1 |
| Humphries, AL | 1 |
| Everhart, JE | 1 |
| Lombardero, M | 1 |
| Lake, JR | 1 |
| Wiesner, RH | 1 |
| Zetterman, RK | 1 |
| Hoofnagle, JH | 1 |
| Carvalho, MF | 1 |
| Soares, V | 1 |
| Reilly, JJ | 1 |
| Brougham, M | 1 |
| Montgomery, C | 1 |
| Richardson, F | 1 |
| Kelly, A | 1 |
| Gibson, BE | 1 |
| Kubo, SH | 1 |
| Peters, JR | 1 |
| Knutson, KR | 1 |
| Hertz, MI | 1 |
| Olivari, MT | 1 |
| Bolman, RM | 1 |
| Hunninghake, DB | 1 |
| Levine, EG | 1 |
| Raczynski, JM | 1 |
| Carpenter, JT | 1 |
| Camoriano, JK | 1 |
| Loprinzi, CL | 1 |
| Ingle, JN | 1 |
| Therneau, TM | 1 |
| Krook, JE | 1 |
| Veeder, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Steroids on Post-tonsillectomy Morbidities[NCT02401529] | Phase 2 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study[NCT00002812] | Phase 3 | 2,078 participants (Actual) | Interventional | 1996-09-30 | Completed | ||
| Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen[NCT01603407] | Phase 3 | 196 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Sarcopenic Obesity and Associated Risk Factors in Patients Undergone Liver Transplant[NCT05029713] | 400 participants (Anticipated) | Observational | 2021-05-10 | Recruiting | |||
| Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2[NCT03333590] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2017-11-06 | Active, not recruiting | ||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
adequacy of meals (inadequate, adequate) (NCT02401529)
Timeframe: 3 days
| Intervention | participants (Number) | |
|---|---|---|
| inadequate | adequate | |
| IV Dexamethasone and Oral Prednisolone | 16 | 34 |
| Placebo | 27 | 23 |
average frequency of meals (1 meal, 2 meals, if more specify) (NCT02401529)
Timeframe: average number of meals consumed per day for the 1st three days post-surgery
| Intervention | participants (Number) | ||
|---|---|---|---|
| 1 meal | 2 meals | 3 meals | |
| IV Dexamethasone and Oral Prednisolone | 2 | 20 | 28 |
| Placebo | 1 | 34 | 15 |
Postoperative nausea duration (no nausea,1 day, 2 days, 3 days, 4 days, if more specify) (NCT02401529)
Timeframe: 7 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| no nausea | one day | two days | three days | |
| IV Dexamethasone and Oral Prednisolone | 33 | 3 | 14 | 0 |
| Placebo | 21 | 8 | 15 | 6 |
4 selections (1 day, 2 days, 3 days, if more specify) (NCT02401529)
Timeframe: number of days at which pain was experienced within the the 1st sevn days post -surgery
| Intervention | participants (Number) | ||
|---|---|---|---|
| one day | two days | three days | |
| IV Dexamethasone and Oral Prednisolone | 36 | 11 | 3 |
| Placebo | 23 | 19 | 8 |
5 grades (pain free, low disability and low intensity, low disability and high intensity, high disability and moderate intensity, high disability and severly limiting) (NCT02401529)
Timeframe: The severest pain grade felt within a week
| Intervention | participants (Number) | ||
|---|---|---|---|
| Low disability and low intensity | high disability and moderate intensity | high disability and high intensity | |
| IV Dexamethasone and Oral Prednisolone | 37 | 13 | 0 |
| Placebo | 26 | 21 | 3 |
Postoperative nausea occurence (yes, no) (NCT02401529)
Timeframe: 7 days
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| IV Dexamethasone and Oral Prednisolone | 17 | 33 |
| Placebo | 29 | 21 |
Postoperative vomiting occurrence (yes, no) (NCT02401529)
Timeframe: 7 days
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| IV Dexamethasone and Oral Prednisolone | 25 | 25 |
| Placebo | 36 | 14 |
feeding onset (1st day i. surgery day, 2nd day, 3rd day) (NCT02401529)
Timeframe: Onset of 1st post-operative oral intake recorded within the 1st 3days post-surgery
| Intervention | participants (Number) | |
|---|---|---|
| surgery day | 1st day after surgery | |
| IV Dexamethasone and Oral Prednisolone | 46 | 4 |
| Placebo | 37 | 13 |
Postoperative nausea onset (no nausea, immediate, 1st day, 2nd day, 3rd day, 4th day, 5th day, 6th day, 7th day) (NCT02401529)
Timeframe: onset of 1st ocurence of nausea attack within the 1st week post-surgery
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| no nausea | immediately | 1st day | immediately and 1st day | |
| IV Dexamethasone and Oral Prednisolone | 33 | 10 | 4 | 3 |
| Placebo | 21 | 8 | 11 | 10 |
Postoperative vomiting number of attacks (no vomiting,1, 2, 3, if more specify) (NCT02401529)
Timeframe: total number of post-operative vomiting episodes which were experienced within the 1st week post-surgery
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| no vomiting | once | twice | three times | more than 3 times | |
| IV Dexamethasone and Oral Prednisolone | 25 | 13 | 7 | 4 | 1 |
| Placebo | 14 | 9 | 19 | 8 | 0 |
Measures the total distance walked in 6 minutes averaged over all post-baseline follow-up visits through Month 36. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | meters (Least Squares Mean) |
|---|---|
| Daily Prednisone | 384.95 |
| Daily Deflazacort | 384.17 |
| Intermittent Prednisone | 346.81 |
Forced vital capacity was measured during a spirometry test. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | liters (Least Squares Mean) |
|---|---|
| Daily Prednisone | 1.4 |
| Daily Deflazacort | 1.4 |
| Intermittent Prednisone | 1.5 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | percentage of fractional shortening (Least Squares Mean) |
|---|---|
| Daily Prednisone | 33.74 |
| Daily Deflazacort | 34.01 |
| Intermittent Prednisone | 34.33 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | bpm (Least Squares Mean) |
|---|---|
| Daily Prednisone | 94.10 |
| Daily Deflazacort | 93.52 |
| Intermittent Prednisone | 91.65 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | percentage of ejection fraction (Least Squares Mean) |
|---|---|
| Daily Prednisone | 61.88 |
| Daily Deflazacort | 62.65 |
| Intermittent Prednisone | 62.45 |
"The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects.~The activities are graded as follows:~2 - Normal - no obvious modification of activity~1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function." (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 23.7 |
| Daily Deflazacort | 24.0 |
| Intermittent Prednisone | 20.7 |
The number of participants who completed 36 months of follow-up on the originally assigned dosage (for weight) of study medication. (NCT01603407)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Daily Prednisone | 36 |
| Daily Deflazacort | 36 |
| Intermittent Prednisone | 37 |
(NCT01603407)
Timeframe: 36 months
| Intervention | kilograms/square meter (Least Squares Mean) |
|---|---|
| Daily Prednisone | 18.9 |
| Daily Deflazacort | 18.3 |
| Intermittent Prednisone | 18.1 |
(NCT01603407)
Timeframe: 36 months
| Intervention | centimeters (Least Squares Mean) |
|---|---|
| Daily Prednisone | 116.8 |
| Daily Deflazacort | 115.3 |
| Intermittent Prednisone | 119.9 |
(NCT01603407)
Timeframe: 36 months
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Daily Prednisone | 26.3 |
| Daily Deflazacort | 24.9 |
| Intermittent Prednisone | 26.3 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | milliseconds (Least Squares Mean) |
|---|---|
| Daily Prednisone | 115.59 |
| Daily Deflazacort | 116.87 |
| Intermittent Prednisone | 117.90 |
Quality of life was measured by parent/guardian self-report for all children utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life for the child. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 64.88 |
| Daily Deflazacort | 63.71 |
| Intermittent Prednisone | 61.33 |
Quality of life was measured by child self-report in children age 5 and older utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 67.39 |
| Daily Deflazacort | 64.96 |
| Intermittent Prednisone | 65.07 |
Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | degrees (Mean) |
|---|---|
| Daily Prednisone | 4.39 |
| Daily Deflazacort | 3.29 |
| Intermittent Prednisone | 2.67 |
Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | degrees (Mean) |
|---|---|
| Daily Prednisone | 4.05 |
| Daily Deflazacort | 2.81 |
| Intermittent Prednisone | 2.29 |
Reciprocal of time to rise from the floor (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | rise/sec (Least Squares Mean) |
|---|---|
| Daily Prednisone | 0.24 |
| Daily Deflazacort | 0.24 |
| Intermittent Prednisone | 0.18 |
The TSQM Global Satisfaction with Treatment is a 14-item questionnaire that ranges from 0 - 100 with higher scores indicating better outcomes. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 71.2 |
| Daily Deflazacort | 67.8 |
| Intermittent Prednisone | 65.1 |
Percentage of fibers expressing GALGT2 in each biopsy sample. (NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | Percentage of Positive Fibers (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 1.95 |
| Cohort 2 | 1.72 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | ng/mg total protein (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 12 |
| Cohort 2 | 14.6 |
(NCT03333590)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 0 |
| Cohort 2 | 0 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1) and Day 180 for both cohorts
| Intervention | meters (Number) | |
|---|---|---|
| Day 90 (Cohort 2) /Day 120 (Cohort 1) | Day 180 | |
| Cohort 1 (Minimal Efficacious Dose) | 320 | 324 |
| Cohort 2 (Minimal Efficacious Dose) | 405 | 416 |
The NSAA provides a score between 0 and 34 where higher numbers represent greater muscle function. (NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | score on a scale (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 1 (Minimal Efficacious Dose) | 16 | 14 | 10 | 6 | 2 |
| Cohort 2 | 21 | 23 | 23 | 23 | 23 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | kg (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 90/Day 120-Right Knee Extension | Day 90/Day 120-Right Knee Flexion | Day 90/Day 120- Left Knee Extension | Day 90/Day 120-Left Knee Flexion | Day 180-Right Knee Extension | Day 180-Right Knee Flexion | Day 180-Left Knee Extension | Day 180-Left Knee Flexion | Month 12-Right Knee Extension | Month 12-Right Knee Flexion | Month 12-Left Knee Extension | Month 12-Left Knee Flexion | Month 18-Right Knee Extension | Month 18-Right Knee Flexion | Month 18-Left Knee Extension | Month 18-Left Knee Flexion | Month 24-Right Knee Extension | Month 24-Right Knee Flexion | Month 24-Left Knee Extension | Month 24-Left Knee Flexion | |
| Cohort 1 (Minimal Efficacious Dose) | 7.42 | 6.06 | 8.78 | 6.12 | 7.13 | 6.1 | 8.66 | 6.69 | 7.49 | 5.67 | 7.5 | 5.32 | 4.55 | 6.11 | 4.96 | 6.26 | 5.06 | 4.41 | 6.93 | 4.17 |
| Cohort 2 | 7.04 | 8.12 | 5.9 | 8.4 | 9.73 | 4.24 | 8.19 | 5.25 | 9.85 | 5.85 | 8.02 | 5.12 | 7.67 | 6.89 | 7.34 | 6.08 | 9.81 | 5.04 | 5.21 | 4.87 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | |||
|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | |
| Cohort 1 (Minimal Efficacious Dose) | 98.2 | 110.9 | 144.5 | 167.8 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 2 | 56.1 | 44.9 | 44.7 | 65.6 | 48.4 |
1 review available for prednisone and Weight Gain
| Article | Year |
|---|---|
Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Humans; Immunosuppressive Agents; Mal | 2003 |
8 trials available for prednisone and Weight Gain
| Article | Year |
|---|---|
Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease.
Topics: Adrenal Cortex Hormones; Adult; Aged; Autoimmune Diseases; Double-Blind Method; Ear, Inner; Female; | 2009 |
Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Double-Blind Method; Drug Therapy, Com | 2013 |
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Hemogl | 1994 |
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)
Topics: Adolescent; Azathioprine; Body Height; Child; Child, Preschool; Double-Blind Method; Drug Therapy, C | 1993 |
Deflazacort in juvenile chronic arthritis.
Topics: Absorptiometry, Photon; Analysis of Variance; Anti-Inflammatory Agents; Arthritis, Juvenile; Bone De | 1993 |
Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia.
Topics: Body Mass Index; Child; Confidence Intervals; Dexamethasone; Energy Intake; Female; Follow-Up Studie | 2001 |
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double- | 1991 |
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double- | 1991 |
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double- | 1991 |
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double- | 1991 |
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
32 other studies available for prednisone and Weight Gain
| Article | Year |
|---|---|
Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.
Topics: Adrenal Cortex Hormones; Adult; Affect; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; | 2021 |
Drug-induced weight gain in the last 10 years: a descriptive study.
Topics: Adalimumab; Adverse Drug Reaction Reporting Systems; Aripiprazole; Databases, Factual; Drug-Related | 2022 |
Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis.
Topics: Adult; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointes | 2020 |
Association between weight change during initial chemotherapy and clinical outcome in dogs with multicentric lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Duration of Ther | 2020 |
No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Linear Models; Male; Middl | 2018 |
Resolution of severe obstructive sleep apnea after treatment of anti-muscle kinase receptor-positive myasthenia gravis despite 60-pound weight gain.
Topics: Anti-Inflammatory Agents; Female; Follow-Up Studies; Humans; Middle Aged; Myasthenia Gravis; Mycophe | 2014 |
Traditional Chinese medication for rheumatoid arthritis: more than what meets the eye.
Topics: Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Female; Humans; Hydrochloro | 2015 |
Wireless capsule endoscopy as a tool in diagnosing autoimmune enteropathy.
Topics: Abdominal Pain; Adult; Azathioprine; Capsule Endoscopy; Diagnosis, Differential; Diarrhea; Female; H | 2015 |
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Topics: Adolescent; Age Factors; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Administratio | 2017 |
Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Dose-Response Relationship, Drug; Drinking; Dr | 2009 |
Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Ind | 2009 |
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
Topics: Adult; Aged; Chi-Square Distribution; Female; Glucocorticoids; Graves Disease; Graves Ophthalmopathy | 2010 |
Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis.
Topics: Administration, Topical; Cataract; Child; Emulsions; Fluprednisolone; Glucocorticoids; Humans; Male; | 2011 |
Interleukin 6 blockade-associated weight gain with abdominal enlargement in a patient with rheumatoid arthritis.
Topics: Abdominal Pain; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Fe | 2013 |
Dietary lipids alter the effect of steroids on the transport of glucose after intestinal resection: Part I. Phenotypic changes and expression of transporters.
Topics: Animals; Blotting, Northern; Blotting, Western; Budesonide; Dexamethasone; Dietary Fats; Dietary Fat | 2003 |
How can I avoid the weight gain that often occurs when taking prednisone?
Topics: Anti-Inflammatory Agents; Body Weight; Humans; Prednisone; Weight Gain | 2003 |
Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Topics: Adolescent; Child; Child, Preschool; Creatinine; Dose-Response Relationship, Drug; Drug Administrati | 2005 |
Development of growth and body mass index after pediatric renal transplantation.
Topics: Antibodies, Monoclonal; Basiliximab; Body Height; Body Mass Index; Child; Cyclosporine; Female; Glom | 2005 |
Losartan attenuates bleomycin-induced pulmonary fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Bleomycin; Body Weigh | 2006 |
Excessive weight gain in cardiac transplant recipients.
Topics: Adult; Age Factors; Aged; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Mid | 2006 |
[Guideline on the use of corticosteroids in Duchenne muscular dystrophy from paediatric neurologists, neurologists and rehabilitation physicians].
Topics: Glucocorticoids; Humans; Male; Muscular Dystrophy, Duchenne; Netherlands; Practice Guidelines as Top | 2006 |
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.
Topics: Adult; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Male; Middle Aged; Prednis | 2008 |
Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Predniso | 1995 |
Influence of treatment modalities on body weight in acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradia | 1996 |
Prednisone can protect against exercise-induced muscle damage.
Topics: Animals; Blotting, Western; Bromodeoxyuridine; Creatine Kinase; Drug Evaluation, Preclinical; Immuno | 1996 |
The impact of pre-transplant obesity on renal transplant outcomes.
Topics: Adult; Azathioprine; Body Mass Index; Cadaver; Cyclosporine; Diabetes Mellitus; Female; Glucocortico | 1997 |
Weight change and obesity after liver transplantation: incidence and risk factors.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Cyclosporine; Female; Glucocorticoids; Graft Rejection | 1998 |
Factors associated with arterial hypertension after renal transplantation.
Topics: Adult; Blood Pressure; Creatinine; Female; Follow-Up Studies; Graft Rejection; Humans; Hypertension; | 1998 |
Factors influencing the development of hypercholesterolemia after cardiac transplantation.
Topics: Adult; Blood Glucose; Cholesterol; Female; Heart Transplantation; Heart-Lung Transplantation; Humans | 1992 |
Weight gain with breast cancer adjuvant treatment.
Topics: Adaptation, Psychological; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1991 |